Sagimet
San Mateo County, California, United States · Biopharma, Biotechnology, Health Care
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors. For more information, please visit www.sagimet
Key facts
- Headquarters
- San Mateo County, California, United States
- Employees
- 14
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (SGMT)
- Website
- sagimet.com
- Company page
Recent activity at Sagimet
- : Sagimet Biosciences closes $115M Series A offering led by Commodore Capital to fund Phase 3 trials and pipeline advancement.
- : Sagimet Biosciences Appoints Andreas Grauer as Chief Medical Officer
- : Sagimet Biosciences Enters Licensing Agreement with TAPI
- : Sagimet Biosciences Appoints Thierry Chauche as Chief Financial Officer
Sagimet funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Post-IPO Equity | $115.0M |
Leadership
- Andreas Grauer, Chief Medical Officer
- Thierry Chauche, Chief Financial Officer
Verified email and direct lines for Sagimet’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Sagimet in the news
- Sagimet Biosciences Announces First Patient Dosed in AURORA - GlobeNewswire (Oct 22, 2026)
- Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - Yahoo Finance (Sep 02, 2026)
- Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne - Dermatology Times (Feb 04, 2026)
- Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance (Aug 11, 2026)
- Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - GlobeNewswire (Oct 01, 2026)
- First patient dosed as Sagimet (SGMT) begins an acne trial set to include 450 teens. - Stock Titan (Oct 22, 2026)
- FDA Grants Denifanstat Breakthrough Therapy Designation for Treatment of MASH - Pharmacy Times (Oct 02, 2024)
- Denifanstat Hits All Targets in Chinese Study - Dermatology Times (Jun 04, 2025)
Companies similar to Sagimet
- LTR Pharma Limited · Biopharma, Biotechnology, Health Care, Pharmaceutical
- TNF Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical
- Sorriso Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical
- Ensho Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical
About Sagimet: questions and answers
What does Sagimet do?
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors. For more information, please visit www.sagimet
Where is Sagimet headquartered?
Sagimet is headquartered in San Mateo County, California, United States.
How many employees does Sagimet have?
Sagimet has about 14 employees.
Has Sagimet raised funding?
Yes. Fundz has recorded 1 funding event for Sagimet. The most recent, Post-IPO Equity of $115.0M, was in Oct 2026.
What is the latest news on Sagimet?
On Oct 01, 2026, Sagimet Biosciences closes $115M Series A offering led by Commodore Capital to fund Phase 3 trials and pipeline advancement.
Is Sagimet a public company?
Yes. Sagimet is publicly traded under the ticker SGMT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy